OSMT - Adamas Beats On Earnings But Misses On Conference Call
Adamas Pharmaceuticals (ADMS), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions (4,740 in Q3) sold. Adamas was able to bring in $34M in net sales and about 15,500 total GOCOVRI prescriptions for 2018. Adamas finished 2018 with a strong cash position of approximately $211M. At first, the market appeared to welcome this news with the share price rising in after-hours trading. This eventually changed to selling